A. Marette

Aguilar

Barthel

BEALE

Bentzinger

Conkright

Cruzado

Cunningham

Daitoku

Dentin

El-Cha  r

Guertin

Herzig

K. Bellmann

Laplante

Morrisett

P. G. Blanchard

Peng

Peterson

Polak

Puigserver

S. Brule

Sarbassov

Stallone

Takano

Tzatsos

V. P. Houde

W. T. Festuccia

Weinstock

Wullschleger

Y. Deshaies

Yoon

Zhang

English

PubMed

Crossref

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange.

A PGC-1alpha-O-GlcNAc transferase complex regulates FoxO transcription factor activity in response to glucose.

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity.

Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3–L1 and human adipocytes.

Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores.

Adiposespeciﬁc knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab

Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway: a negative feedback mechanism leading to insulin resistance in skeletal muscle cells.

Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI 3-kinase activity but inhibits Akt2 and glucose transport stimulation in 3T3–L1 adipocytes. Mol Endo.

Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1.

CREB regulates hepatic gluconeogenesis through the coactivator PGC-1.

Depot-speciﬁc effects of the PPARgamma agonist rosiglitazone on adipose tissue glucose uptake and metabolism.

Depot-speciﬁc modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner.

Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients.

FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression.

Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.

Glyceroneogenesis comes of age.

Identiﬁcation of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance.

Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance.

Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1.

Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2.

Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback downregulates protein kinase B-mediated signaling pathway in beta-cells.

Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One

Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction.

Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deﬁcient in adipose tissue lipoprotein lipase. Proc Natl Acad SciUSA

Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin.

Management of side effects of sirolimus therapy. Transplantation

Mechanisms of the depot speciﬁcity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism.

mTOR complex 2 in adipose tissue negatively controls whole-body growth.

mTOR controls mitochondrial oxidative function through a YY1-PGC1alpha transcriptional complex.

Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev (Orlando)

Novel concepts in insulin regulation of hepatic gluconeogenesis.

Nutrient-dependent and insulinstimulated phosphorylation of insulin receptor substrate-1 on serine 302 correlates with increased insulin signaling.

Nutrients suppress phosphatidylinositol 3-kinase/ Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation.

PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control.

Regulation of hepatic fasting response by PPARgamma coactivator1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis.

regulation of peroxisome proliferator-activated receptorgamma activity by mammalian target of rapamycin and amino acids in adipogenesis.

Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR.

S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab

Skeletal muscle-speciﬁc ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy.

Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance.

The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation.

Thematic review series: glycerolipids: multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolism.

Tissue-speciﬁc regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha.

TOR signaling in growth and metabolism.

TORCs: transducers of regulated CREB activity.

Upregulation of the mTOR complex 1 pathway by Rheb in pancreatic  cells leads to increased  cell mass and prevention of hyperglycemia. Diabetes Published online before print

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2874694

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

Abstract

Similar works

Full text

Available Versions

Crossref